ATE144143T1 - Künstlicher impfstoff gegen aids-virus - Google Patents

Künstlicher impfstoff gegen aids-virus

Info

Publication number
ATE144143T1
ATE144143T1 AT89908567T AT89908567T ATE144143T1 AT E144143 T1 ATE144143 T1 AT E144143T1 AT 89908567 T AT89908567 T AT 89908567T AT 89908567 T AT89908567 T AT 89908567T AT E144143 T1 ATE144143 T1 AT E144143T1
Authority
AT
Austria
Prior art keywords
vaccine against
aids virus
against aids
artificial
artificial vaccine
Prior art date
Application number
AT89908567T
Other languages
English (en)
Inventor
Jay A Berzofsky
Paula M Eaton Way Hale
Anne Hosmalin
Hanah Margalit
John L Spouge
James L Cornette
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE144143T1 publication Critical patent/ATE144143T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/22—Viral peptide or viral protein
    • Y10S930/221—Retrovirus related, or human immunodeficiency virus related, or simian immunodeficiency virus related

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT89908567T 1988-07-21 1989-07-19 Künstlicher impfstoff gegen aids-virus ATE144143T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/222,684 US5030449A (en) 1988-07-21 1988-07-21 Synthetic vaccine against AIDS virus

Publications (1)

Publication Number Publication Date
ATE144143T1 true ATE144143T1 (de) 1996-11-15

Family

ID=22833252

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89908567T ATE144143T1 (de) 1988-07-21 1989-07-19 Künstlicher impfstoff gegen aids-virus

Country Status (9)

Country Link
US (1) US5030449A (de)
EP (1) EP0429477B1 (de)
JP (1) JP2676166B2 (de)
AT (1) ATE144143T1 (de)
AU (1) AU624628B2 (de)
CA (1) CA1339240C (de)
DE (1) DE68927348T2 (de)
IL (1) IL91007A (de)
WO (1) WO1990000901A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939074A (en) * 1986-12-30 1999-08-17 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptide antigens
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
US6210873B1 (en) 1987-08-28 2001-04-03 Board Of Regents, The University Of Texas System Methods and compositions for the priming of specific cytotoxic T-lymphocyte response
US5456924A (en) * 1988-12-23 1995-10-10 Immunotec Research Corporation Ltd. Method of treatment of HIV-seropositive individuals with dietary whey proteins
EP0362909A3 (de) * 1988-08-26 1990-11-14 Akzo N.V. Synthetische Polypeptide, immunochemisch aktiv mit HIV-Antikörpern
CA2035576A1 (en) * 1990-02-07 1991-08-08 Alexander R. Neurath Conformational epitopes of human immunodeficiency virus envelope glycoprotein gp120 hiv-1
AU641814B2 (en) * 1990-09-25 1993-09-30 Peptech (Uk) Limited Aids therapy and vaccine
AU669329B2 (en) * 1991-03-22 1996-06-06 Trustees Of The University Of Pennsylvania, The Method of modulating mammalian T-cell response
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
CA2114849C (en) * 1991-08-29 2007-04-24 Jay A. Berzofsky Multideterminant peptide antigens that stimulate helper t lymphocyte response to hiv in a range of human subjects
DE69230769T2 (de) * 1991-12-02 2000-07-13 Board Of Regents, The University Of Texas System Zusammensetzungen zum auslösen cytotoxischer t-lymphozyten gegen viren
WO1993019775A1 (en) * 1992-03-31 1993-10-14 Medimmune, Inc. Administration of liposomes containing peptides or proteins including ctl eptitopes of hiv proteins
AU688733B2 (en) * 1992-07-20 1998-03-19 Duke University Compounds which inhibit HIV replication
DE4228787A1 (de) 1992-08-29 1994-03-03 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Neue HIV-1-Virusisolate eines Subtyps, Vakzine gegen HIV-1-Virusinfektionen dieses Subtyps und Verfahren zu ihrer Herstellung, Verwendung der HIV-1-Virusisolate
JP3277045B2 (ja) * 1992-10-06 2002-04-22 デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング Ｈｉｖ−グループのレトロウイルスおよびその使用
US5607914A (en) * 1993-01-13 1997-03-04 Pioneer Hi-Bred International, Inc. Synthetic antimicrobial peptides
US5869624A (en) * 1993-03-26 1999-02-09 Progenics Pharmaceuticals, Inc. HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof
US5603933A (en) * 1993-08-31 1997-02-18 Board Of Regents, The University Of Texas CD4 peptides for binding to viral envelope proteins
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
US6749856B1 (en) * 1997-09-11 2004-06-15 The United States Of America, As Represented By The Department Of Health And Human Services Mucosal cytotoxic T lymphocyte responses
IL150961A0 (en) 2000-02-04 2003-02-12 Univ Duke Human immunodeficiency virus vaccine
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
WO2006071989A2 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
MX2013010924A (es) * 2011-03-23 2014-11-10 Smart Biotech Ltd Metodo y equipo para estimar incidencia de virus de inmunodeficiencia humana (vih).
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
AU2015277194B2 (en) 2014-06-17 2020-10-22 The Research Foundation For The State University Of New York Ship inhibition to induce activation of natural killer cells
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002775A1 (en) * 1985-10-24 1987-05-07 Southwest Foundation For Biomedical Research Synthetic peptides and use for diagnosis and vaccination for aids and arc
WO1988005051A1 (en) * 1986-12-30 1988-07-14 United States Of America, Represented By The Unite Synthetic peptides which induce cellular immunity of the aids virus and aids viral proteins
WO1989007112A1 (en) * 1988-01-26 1989-08-10 The United States Of America, As Represented By Th A synthetic antigen evoking anti-hiv response
EP0330359A3 (de) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Zusammensetzung, verwendbar zur Diagnose und Behandlung von HIV-I-Infektion

Also Published As

Publication number Publication date
DE68927348T2 (de) 1997-02-13
EP0429477B1 (de) 1996-10-16
EP0429477A4 (en) 1991-11-13
IL91007A (en) 1995-08-31
JPH03504384A (ja) 1991-09-26
US5030449A (en) 1991-07-09
WO1990000901A1 (en) 1990-02-08
AU624628B2 (en) 1992-06-18
DE68927348D1 (de) 1996-11-21
AU3967089A (en) 1990-02-19
EP0429477A1 (de) 1991-06-05
IL91007A0 (en) 1990-02-09
JP2676166B2 (ja) 1997-11-12
CA1339240C (en) 1997-08-05

Similar Documents

Publication Publication Date Title
DE68927348D1 (de) Künstlicher impfstoff gegen aids-virus
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
DE69333397D1 (de) Retro-, inverso-, und retro-inverso synthetische peptidanaloge
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
ATE64601T1 (de) Lymphadenopathie-assoziierte huellenantigene und deren verwendungen.
GB2255093A (en) Hiv-1 core protein fragments
ATE397014T1 (de) Hiv-peptide, antigene und impfstoffzusammensetzungen
ES2100240T3 (es) Bacteriofagos modificados mediante ingenieria genetica y vacunas que los contienen.
WO1989002277A3 (en) Prophylaxis and therapy of acquired immunodeficiency syndrome
ITRM920350A1 (it) Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
ES2143996T3 (es) Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv.
ATE248601T1 (de) Impfstoff gegen rotavirus infektionen enthaltend peptide des viralenterotoxines nsp4
AU6683400A (en) Vaccine against lentiviral infections, such as the feline immune deficiency virus of the cat
DK56389A (da) Forhindring og behandling af retroviralt frembragte sygdomme
EP0652769A1 (de) Impfstoffe gegen MetazoonParasiten.
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
ES2080024B1 (es) Vacuna subunitaria recombinante contra la enfermedad hemorragica virica de los conejos.
DE69428984D1 (de) Stimulierung der immunantwort durch virales protein
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
MX9301736A (es) Vacuna de bacterina-toxoide de pasteurella haemolytica tipo a-1.
IT1233419B (it) Peptidi sintetici immunologicamente attivi utili per la preparazione di un vaccino antimalaria
DK0555333T3 (da) Kunstige virushylstre
ES2085908T3 (es) Antigenos de la glucoproteina transmembranica de cubierta de un retrovirus humano del tipo hiv-2 (antigenos que presentan entre ellos un parentesco inmunologico).
ES8801958A1 (es) Un procedimiento para la determinacion de virus de sida
FR2792639B1 (fr) Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee